The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma

Gut

Volumn 64, Issue 9, 2015, Pages 1454-1465

  Rovida, Elisabetta ^a   Di Maira, Giovanni ^a   Tusa, Ignazia ^a   Cannito, Stefania ^b   Paternostro, Claudia ^b   Navari, Nadia ^a   Vivoli, Elisa ^a   Deng, Xianming ^c,d   Gray, Nathanael S ^c   Esparís Ogando, Azucena ^e   David, Ezio ^f   Pandiella, Atanasio ^e   Sbarba, Persio Dello ^a   Parola, Maurizio ^b   Marra, Fabio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d XIAMEN UNIVERSITY   (China)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P15; PROTEIN P27; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; XMD 8 92;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER TISSUE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; MOUSE; NEEDLE BIOPSY; PATHOLOGY; PATHOPHYSIOLOGY; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 7; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 84941270270     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-306761     Document Type: Article

References (50)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
2. Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013;144:512-27.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
4. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 1995;213:715-24.
5. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem 1995;270:12665-9.
6. Drew BA, Burow ME, Beckman BS. MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta 2012;1825:37-48.
7. Nithianandarajah-Jones GN, Wilm B, Goldring CE, et al. ERK5: structure, regulation and function. Cell Signal 2012;24:2187-96.
8. Lochhead PA, Gilley R, Cook SJ. ERK5 and its role in tumour development. Biochem Soc Trans 2012;40:251-6.
9. Zen K, Yasui K, Nakajima T, et al. ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer 2009;48:109-20.
10. Liu LX, Liu ZH, Jiang HC, et al. Gene expression profiles of hepatoma cell line HLE. World J Gastroenterol 2003;9:683-7.
11. Novo E, Povero D, Busletta C, et al. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J Pathol 2012;226:588-97.
12. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497-9.
13. Nakabayashi H, Taketa K, Miyano K, et al. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-63.
14. Di Maira G, Brustolon F, Bertacchini J, et al. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 2007;26:6915-26.
15. Rovida E, Navari N, Caligiuri A, et al. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J Hepatol 2008;48:107-15.
16. Barbetti V, Morandi A, Tusa I, et al. Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells. Oncogene 2014;33:4359-64.
17. Bonacchi A, Romagnani P, Romanelli RG, et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001;276:9945-54.
18. Barbetti V, Gozzini A, Cheloni G, et al. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics 2013;8:210-19.
19. Yang Q, Deng X, Lu B, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010;18:258-67.
20. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995;20:187-90.
21. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005;24:7410-25.
22. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012;55:622-33.
23. Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008;29:2267-78.
24. Behrens A, Sibilia M, David JP, et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J 2002;21:1782-90.
25. Kato Y, Kravchenko VV, Tapping RI, et al. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997;16:7054-66.
26. Kato Y, Zhao M, Morikawa A, et al. Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J Biol Chem 2000;275:18534-40.
27. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
28. Yano H, Mazaki Y, Kurokawa K, et al. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol 2004;166:283-95.
29. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68.
30. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010;123:1007-13.
31. Villa-Moruzzi E. Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. Anal Cell Pathol (Amst) 2011;34:101-12.
32. Villa-Moruzzi E. Targeting of FAK Ser910 by ERK5 and PP1delta in non-stimulated and phorbol ester-stimulated cells. Biochem J 2007;408:7-18.
33. Sawhney RS, Liu W, Brattain MG. A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 2009;219:152-61.
34. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307.
35. Sohn SJ, Sarvis BK, Cado D, et al. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 2002;277:43344-51.
36. Pi X, Garin G, Xie L, et al. BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1alpha. Circ Res 2005;96:1145-51.
37. Marchetti A, Colletti M, Cozzolino AM, et al. ERK5/MAPK is activated by TGFbeta in hepatocytes and required for the GSK-3beta-mediated Snail protein stabilization. Cell Signal 2008;20:2113-18.
38. Mulloy R, Salinas S, Philips A, et al. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 2003;22:5387-98.
39. Rovida E, Spinelli E, Sdelci S, et al. ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J Immunol 2008;180:4166-72.
40. Perez-Madrigal D, Finegan KG, Paramo B, et al. The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell Signal 2012;24:2360-8.
41. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
42. Wang X, Finegan KG, Robinson AC, et al. Activation of extracellular signal-regulated protein kinase 5 downregulates FasL upon osmotic stress. Cell Death Differ 2006;13:2099-108.
43. Cude K, Wang Y, Choi HJ, et al. Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 2007;177:253-64.
44. Pearson G, English JM, White MA, et al. ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 2001;276:7927-31.
45. Gieling RG, Elsharkawy AM, Caamano JH, et al. The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation. Hepatology 2010;51:922-31.
46. Nguyen H, Sankaran S, Dandekar S. Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology 2006;354:58-68.
47. McCracken SR, Ramsay A, Heer R, et al. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 2008;27:2978-88.
48. Erazo T, Moreno A, Ruiz-Babot G, et al. Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. Mol Cell Biol 2013;33:1671-86.
49. Diaz-Rodriguez E, Pandiella A. Multisite phosphorylation of Erk5 in mitosis. J Cell Sci 2010;123:3146-56.
50. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.